The Influence of miRNAs on Radiotherapy Treatment in Prostate Cancer – A Systematic Review

In the last years, extensive investigation on miRNomics have shown to have great advantages in cancer personalized medicine regarding diagnosis, treatment and even clinical outcomes. Prostate cancer (PCa) is the second most common male cancer and about 50% of all PCa patients received radiotherapy (RT), despite some of them develop radioresistance. Here, we aim to provide an overview on the mechanisms of miRNA biogenesis and to discuss the functional impact of miRNAs on PCa under radiation response. As main findings, 23 miRNAs were already identified as being involved in genetic regulation of PCa cell response to RT. The mechanisms of radioresistance are still poorly understood, despite it has been suggested that miRNAs play an important role in cell signaling pathways. Identification of miRNAs panel can be thus considered an upcoming and potentially useful strategy in PCa diagnosis, given that radioresistance biomarkers, in both prognosis and therapy still remains a challenge.

Abstract licence: CC BY

1. 9.

   Human MicroRNA Oncogenes and Tumor Suppressors Show Significantly Different Biological Patterns: From Functions to Targets · 2010

2. 13.

   MicroRNA Let-7a Inhibits Proliferation of Human Prostate Cancer Cells In Vitro and In Vivo by Targeting E2F2 and CCND2 · 2010

3. 19.

   An Analysis of Human MicroRNA and Disease Associations · 2008

4. 39.

   MicroRNA: Biogenesis, Function and Role in Cancer · 2010

5. 59.

   Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3 · 2016

6. 66.

   New Insight into microRNA Functions in Cancer: Oncogene–microRNA–Tumor Suppressor Gene Network · 2017

7. 67.

   The role of MicroRNAs in human cancer · 2016

8. 72.

   The hypoxic tumour microenvironment · 2018

9. 77.

   Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage · 2018

10. 90.

    ROS and the DNA damage response in cancer · 2019

11. 94.

    MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer · 2019

12. 96.

    Circulating MicroRNAs in Cancer: Potential and Challenge · 2019

101 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.